Novartis AG Revenue 2006-2018 | NVS

Current and historical revenue for Novartis AG (NVS) from 2006 to 2018. Revenue can be defined as the sum of all revenue fields included for a company's operating activities. Novartis AG revenue for the twelve months ending June 30, 2018 was $52.237B. Novartis AG revenue for the three months ending June 30, 2018 was $13.452B, representing a 7.67% increase from the same quarter last year.
Novartis AG Annual Revenue
(Millions of US $)
2017 $50,135
2016 $49,436
2015 $50,387
2014 $53,634
2013 $52,716
2012 $51,971
2011 $59,375
2010 $51,561
2009 $45,103
2008 $42,584
2007 $38,947
2006 $35,105
2005 $29,753
Novartis AG Quarterly Revenue
(Millions of US $)
Q2 2018 $13,452
Q1 2018 $12,929
Q4 2017 $13,164
Q3 2017 $12,692
Q2 2017 $12,494
Q1 2017 $11,785
Q4 2016 $12,606
Q3 2016 $12,341
Q2 2016 $12,679
Q1 2016 $11,810
Q4 2015 $12,804
Q3 2015 $12,485
Q2 2015 $12,896
Q1 2015 $12,202
Q4 2014 $13,354
Q3 2014 $13,300
Q2 2014 $13,949
Q1 2014 $13,031
Q4 2013 $12,324
Q3 2013 $12,906
Q2 2013 $13,280
Q1 2013 $14,206
Q4 2012 $9,478
Q3 2012 $14,039
Q2 2012 $14,541
Q1 2012 $13,913
Q4 2011 $14,996
Q3 2011 $15,034
Q2 2011 $15,123
Q1 2011 $14,222
Q4 2010 $14,464
Q3 2010 $12,820
Q2 2010 $11,921
Q1 2010 $12,356
Q4 2009 $13,145
Q3 2009 $11,290
Q2 2009 $10,742
Q1 2009 $9,926
Q4 2008 $10,348
Q3 2008 $11,030
Q2 2008 $10,990
Q1 2008 $10,216
Q4 2007 $10,171
Q3 2007 $9,818
Q2 2007 $9,584
Q1 2007 $9,374
Q4 2006 $9,260
Q3 2006 $9,024
Q2 2006 $8,671
Q1 2006 $8,150
Q4 2005 $5,980
Q3 2005 $8,489
Q2 2005 $7,870
Q1 2005 $7,414
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $191.051B $49.109B
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $349.368B 16.69
Pfizer (PFE) United States $242.936B 14.22
Merck (MRK) United States $179.890B 15.89
AbbVie (ABBV) United States $146.551B 14.32
Novo Nordisk (NVO) Denmark $115.579B 18.48
Eli Lilly (LLY) United States $110.019B 20.37
Sanofi (SNY) France $104.111B 13.18
AstraZeneca (AZN) United Kingdom $98.834B 10.87
GlaxoSmithKline (GSK) United Kingdom $98.627B 13.17
Bristol-Myers Squibb (BMY) United States $97.124B 17.58